世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

デジタルバイオマーカー市場の規模、シェア、動向分析レポート:タイプ別(ウェアラブル、モバイルベースアプリケーション、センサー)、臨床診療別、治療領域別、最終用途別、地域別、セグメント別予測、2022年~2030年


Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile based Applications, Sensors), By Clinical Practice, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2022 - 2030

デジタルバイオマーカー市場の成長と動向 Grand View Research社の最新レポートによると、デジタルバイオマーカーの世界市場規模は、予測期間中に21.9%のCAGRを記録し、2030年までに139億616万米ドルに達する... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2022年10月25日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
150 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

デジタルバイオマーカー市場の成長と動向

Grand View Research社の最新レポートによると、デジタルバイオマーカーの世界市場規模は、予測期間中に21.9%のCAGRを記録し、2030年までに139億616万米ドルに達すると予測されています。最近の進歩や遠隔技術の受け入れが進んでいることから、デジタルバイオマーカーの市場は予測期間を通じて拡大すると予想されています。デジタルバイオマーカー市場の最大セグメントを構成する遠隔データ収集技術の開発は、ウェアラブルおよびモバイル技術の改善によって推進されています。さらに、この市場セグメントは、インターネットの利用が拡大していることによって、さらに支援されています。

特に、音声デジタルバイオマーカーは最近登場し、大きなビジネス展開の可能性を秘めています。音声記録や携帯電話、ウェアラブル端末などの患者所有の技術を通じて、簡単にデータを収集することができます。音声バイオマーカーは、医療システムの負担を軽減し、身体的または精神的疾患の早期介入と早期発見を強化することで患者の転帰を改善し、予測期間中の市場の拡大を後押しする可能性がある。

さらに、市場のプレゼンスを獲得し、予測期間中に収益市場シェアをさらに高めるために、プレイヤーは音声デジタルバイオマーカーの探索も始めています。例えば、2021年10月、Sonde health社は、音声対応メンタルフィットネスモニタリング技術プラットフォームを発表しました。

さらに、慢性疾患や神経変性疾患の有病率の上昇や、これらの疾患をうまくコントロールするための薬剤開発の強化の必要性が高まっていることから、予測期間中に市場は大幅に拡大すると予想されます。デジタルバイオマーカーは、従来の臨床試験プロセスとは異なり、新薬の開発を加速させることができます。

分散型臨床試験プラットフォームのプロバイダーの1つであるMed ableの調査によると、すべての臨床試験の85.0%が何らかの遅延を経験しており、遅延による経済的影響は1日あたり60万米ドルから800万米ドルに上ります。分散型臨床試験では、第2相試験の時間を最大で1~3カ月短縮できる可能性があるとされています。その結果、医薬品メーカーはDCTのデジタルバイオマーカーに資金を投入しており、市場拡大を促進すると予想されます。例えば、アストラゼネカは2022年3月、遠隔デジタルバイオマーカーに基づく分散型臨床試験を提供する英国のHUMA社に3300万米ドルを投資したと表明している。この提携により、DCTの採用を加速させる。

先見の明のある市場参加者は、将来の成功に必要な幅広い技術力とサービスを活用し、デジタル・バイオマーカーの世界市場における自社のポジションを強化するために、決定を拡大し、典型的なサプライヤーを超えて行動しています。これらの企業は、製品の上市、ジョイントベンチャー、M&Aなど、さまざまな戦略を採用しています。例えば、ファイザーは2022年4月に、患者の咳の声を用いて人工知能で呼吸器疾患の重症度を測定・判定するアプリを開発したオーストラリア拠点のスタートアップ、ResApp社を買収しました。

デジタルバイオマーカー市場レポートハイライト

- 2021年の治療分野別セグメントでは、心血管・代謝疾患(CVMD)が20.0%以上の高い収益シェアを占めており、世界中の患者集団における心血管疾患の有病率が上昇していることから、今後も大きな主要存在であり続けると予想されます。一方、COVID-19や新たな新技術により、予測期間中、呼吸器疾患の市場収益シェアは最も速い速度で拡大すると予想される

- 臨床疾患や日常生活のために意味される診断モニタリングの使用が増加しているため、診断用デジタルバイオマーカーは2021年に臨床診療セグメントで最大の収益シェアを占めた。さらに、予測期間中、モニタリング用デジタルバイオマーカーの収益が最も速く拡大すると予想される

- ウェアラブルは、最先端のウェアラブルスマートウォッチなどの新製品の発売により、2021年のデジタルバイオマーカー種類別セグメントで39.0%以上の収益シェアを獲得した。スマートフォンが世界中で広く利用されるようになった結果、予測期間中、モバイルベースのアプリケーションの収益シェアが最も速い速度で成長すると予測される。また、新技術やセンサーの利用が進むことで、予測期間中に激しい競争が繰り広げられると予想されます。

- エンドユースカテゴリーでは、適応症の増加や費用対効果の高い臨床試験および製品分析戦略への要求から、ヘルスケア企業が2021年に50.0%を超える最大の市場シェアを占めている。

- 北米は、確立された高度な医療インフラと研究開発活動への多額の支出の結果、2021年に市場を支配し、総収入の59.0%以上のシェアを獲得した。さらに、予測期間中はヨーロッパが最も速い成長率を示すだろう

- 提携、買収、合併、製品の発売を行うことで、主要企業も市場の拡大に貢献しています。例えば、2021年にMed ableは、デジタルバイオマーカー事業のAural Analyticsと提携し、遠くのスピーチパターンを測定し、健康状態や衰えの段階を監視している



ページTOPに戻る


目次

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Report Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Digital BiomarkersMarket Summary, 2021
Chapter 3 Digital Biomarkers Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Digital Biomarkers Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increased Popularity of Recent Innovations and Remote Technologies
3.3.1.2 Rising Usage of Smartphones and The Emergence of New Wearables
3.3.1.3 Expanding Therapeutic Area Application
3.3.1.4 Increasing Investment in Decentralized Clinical Trials
3.3.2 Market Restraints Analysis
3.3.2.1 Concerns about Data Privacy
3.3.2.1 Lack of Awareness and Poor Skilled Professionals in Emerging Economics
3.4 Digital Biomarkers Market Analysis Tools: Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Threat Of Substitutes
3.4.4 Threat Of New Entrants
3.4.5 Competitive Rivalry
3.5 Pestel Analysis
3.5.1 Political & Legal Landscape
3.5.2 Social Landscape
3.5.3 Technology Landscape
3.5.4 Environmental Analysis
3.6 Regulatory Framework
3.7 Technology Overview
3.8 Pricing Analysis
3.9 Covid-19 Impact Analysis
3.9.1 Current And Future Impact Analysis
3.9.2 Impact Of Covid-19 On Market Players
Chapter 4 Competitive Landscape
4.1 Market participation categorization
4.2 Public Companies
4.2.1 Company Market Position Analysis
4.2.2 Synergy Analysis: Major Deals & Strategic Alliances
4.3 Detailed list of market players
Chapter 5 Digital Biomarkers Market: Segment Analysis, by type, 2017 - 2030 (USD Million)
5.1 Type Movement Analysis, 2021 & 2030
5.1.1 Wearable
5.1.1.1 Wearable Market Estimates and Forecasts, 2017 - 2030 (Million)
5.1.2 Mobile Based Applications
5.1.2.1 Mobile Based Applications Market Estimates and Forecasts, 2017 - 2030 (Million)
5.1.3 Sensors
5.1.3.1 Sensors Market Estimates and Forecasts, 2017 - 2030 (Million)
5.1.4 Others
5.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 6 Digital Biomarkers Market: Segment Analysis, by Clinical Practice, 2017 - 2030 (USD Million)
6.1 Clinical Practice Movement Analysis, 2021 & 2030
6.1.1 Diagnostic Digital Biomarkers
6.1.1.1 Diagnostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
6.1.2 Monitoring Digital Biomarkers
6.1.2.1 Monitoring Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
6.1.3 Predictive and Prognostic Digital Biomarkers
6.1.3.1 Predictive and Prognostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
6.1.4 Others
6.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 7 Digital Biomarkers Market: Segment Analysis, by Therapeutic Area, 2017 - 2030 (USD Million)
7.1 Therapeutic Area Movement Analysis, 2021 & 2030
7.1.1 Cardiovascular and Metabolic Disorders (CVMD)
7.1.1.1 Cardiovascular and Metabolic Disorders (CVMD) Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.2 Respiratory Disorders
7.1.2.1 Respiratory Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.3 Psychiatric Disorders
7.1.3.1 Psychiatric Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.4 Sleep & Movement Disease
7.1.4.1 Sleep & Movement Disease Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.5 Neurological Disorders
7.1.5.1 Neurological Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.6 Musculoskeletal Disorders
7.1.6.1 Musculoskeletal Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.7 Others
7.1.7.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 8 Digital Biomarkers Market: Segment Analysis, by End-Use, 2017 - 2030 (USD Million)
8.1 End-Use Movement Analysis, 2021 & 2030
8.1.1 Healthcare Companies
8.1.1.1 Healthcare Companies Market Estimates and Forecasts, 2017 - 2030 (Million)
8.1.2 Healthcare Providers
8.1.2.1 Healthcare ProvidersMarket Estimates and Forecasts, 2017 - 2030 (Million)
8.1.3 Payers
8.1.3.1 Payers Market Estimates and Forecasts, 2017 - 2030 (Million)
8.1.4 Others
8.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 9 Digital Biomarkers Market: Regional Market Analysis, by type, clinical practice, therapeutic area, and end-Use, 2017 - 2030 (USD Million)
9.1 Market Size, & Forecasts, Volume, and Trend Analysis, 2017 to 2030
9.2 North America
9.2.1 North America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.2.2 U.S.
9.2.2.1 U.S. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.2.3 Canada
9.2.3.1 Canada Digital Biomarkers Market Estimates and Forecasts, 2017 -2030 (Million)
9.3 Europe
9.3.1 Europe Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.2 U.K.
9.3.2.1 U.K. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.3 Germany
9.3.3.1 Germany Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.4 Netherlands
9.3.4.1 Netherlands Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.5 Italy
9.3.5.1 Italy Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.6 Switzerland
9.3.6.1 Switzerland Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.2 Japan
9.4.2.1 Japan Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.3 China
9.4.3.1 China Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.4 Australia
9.4.4.1 Australia Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.5 India
9.4.5.1 India Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.6 South Korea
9.4.6.1 South Korea Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.5 Latin America
9.5.1 Latin America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.5.2 Brazil
9.5.2.1 Brazil Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.5.3 Mexico
9.5.3.1 Mexico Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.6 MEA
9.6.1 MEA Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.6.2 South Africa
9.6.2.1 South Africa Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.6.3 Israel
9.6.3.1 Israel Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 10 Company Profiles
10.1 ActiGraph LLC
10.1.1 Company Overview
10.1.2 Financial Performance
10.1.3 Product Benchmarking
10.1.4 Strategic Initiatives
10.2 AliveCor Inc
10.2.1 Company Overview
10.2.2 Financial Performance
10.2.3 Product Benchmarking
10.2.4 Strategic Initiatives
10.3 Koneksa
10.3.1 Company Overview
10.3.2 Financial Performance
10.3.3 Product Benchmarking
10.3.4 Strategic Initiatives
10.4 Amgen Inc.
10.4.1 Company Overview
10.4.2 Financial Performance
10.4.3 Product Benchmarking
10.4.4 Strategic Initiatives
10.5 Biogen Inc.
10.5.1 Company Overview
10.5.2 Financial Performance
10.5.3 Product Benchmarking
10.5.4 Strategic Initiatives
10.6 Altoida Inc
10.6.1 Company Overview
10.6.2 Financial Performance
10.6.3 Product Benchmarking
10.6.4 Strategic Initiatives
10.7 IXICO plc
10.7.1 Company Overview
10.7.2 Financial Performance
10.7.3 Product Benchmarking
10.7.4 Strategic Initiatives
10.8 Adherium Limited
10.8.1 Company Overview
10.8.2 Financial Performance
10.8.3 Product Benchmarking
10.8.4 Strategic Initiatives
10.9 Empatica Inc
10.9.1 Company Overview
10.9.2 Financial Performance
10.9.3 Product Benchmarking
10.9.4 Strategic Initiatives
10.10 Huma
10.10.1 Company Overview
10.10.2 Financial Performance
10.10.3 Product Benchmarking
10.10.4 Strategic Initiatives
10.11 VivoSense
10.11.1 Company Overview
10.11.2 Financial Performance
10.11.3 Product Benchmarking
10.11.4 Strategic Initiatives
10.12 ResApp (Pfizer)
10.12.1 Company Overview
10.12.2 Financial Performance
10.12.3 Product Benchmarking
10.12.4 Strategic Initiatives

 

ページTOPに戻る


 

Summary

Digital Biomarkers Market Growth & Trends

The global digital biomarkers market size is expected to reach USD 13,966.16 million by 2030, registering a CAGR of 21.9% during the forecast period, according to a new report by Grand View Research, Inc. Due to the rising acceptance of recent advancements and remote technologies, the market for digital biomarkers is anticipated to expand throughout the forecast period. Development of the remote data collecting technologies, which make up the largest segment of the market for digital biomarkers, has been propelled by the improvements in wearable and mobile technology. Additionally, this market segment is being further assisted by the growing use of the internet.

Vocal digital biomarkers in particular have lately come into existence and offer enormous business development potential. They enable easy data collection through voice recordings and through patient-owned technology like cell phones, wearables, and other devices. Vocal biomarkers are being utilized more frequently, which might ease the strain on the healthcare systems and improve patient outcomes by enhancing early intervention and before-time identification of physical or mental illnesses, boosting the market's expansion during the forecast period.

Furthermore, in order to acquire market presence and further boost its revenue market share during the forecast, players have also begun exploring the vocal digital biomarkers. For instance, in October 2021, Sonde health launched a voice-enabled mental fitness monitoring technology platform.

Additionally, the market is anticipated to experience substantial expansion during the forecast period due to the rising prevalence of chronic diseases and neurodegenerative diseases, as well as the growing need for enhanced drug development to successfully control these diseases. In comparison to the conventional clinical trial process, digital biomarkers accelerate the development of new drugs.

According to a study by one of the well-known decentralized trial platform providers, Med able, 85.0% of all clinical trials experience some sort of delay, with the financial impact of delays costing between USD 600,000 and USD 8 million per day, decentralized clinical trials could save up to 1 to 3 months of time in phase 2 studies. As a result, medicine manufacturers are spending money on a digital biomarker for DCT, which is anticipated to fuel market expansion. For instance, AstraZeneca stated in March 2022 that it had invested USD 33.0 million in Huma, a UK-based company that provides decentralized clinical trials based on remote digital biomarkers. Through this alliance, the company will quicken the adoption of DCT.

Forward-thinking market participants are expanding their decisions and moving beyond typical suppliers in order to strengthen the company’s position in the global market for digital biomarkers by utilizing the wide range of technology capabilities and services required for future success. These companies have employed a variety of strategies such as product launches, joint ventures, and mergers & acquisitions. For instance, in April 2022, Pfizer acquired ResApp, an Australian- based startup that had created an app that uses artificial intelligence to gauge and determine the severity of respiratory problems using the coughing voice of a patient.

Digital Biomarkers Market Report Highlights

• Cardiovascular and metabolic disorders (CVMD) had the highest revenue share of more than 20.0% in the therapeutic area segment in 2021 and is anticipated that it will continue to have a significant major presence given the rising prevalence of cardiovascular diseases among patient populations around the globe. On the other hand, due to COVID-19 and emerging new technologies, it is anticipated that during the forecast period, market revenue share for respiratory disorders will expand at the fastest rate

• Due to the growing use of diagnostic monitoring meant for clinical disease and daily living, diagnostic digital biomarkers had the largest revenue share in the clinical practice segment in 2021. Moreover, the fastest revenue growth is anticipated for monitoring digital biomarkers during the forecast period

• Wearable had a revenue share of more than 39.0% in the digital biomarker type segment in 2021, due to the release of new, cutting-edge wearable smart watches and other products. As a result of the extensive usage of smartphones, worldwide, it is anticipated that revenue share growth for mobile-based applications would happen at the fastest rate during the forecast period. Additionally, rising usage of new technologies, and sensors, would also confront intense competition during the forecast period

• Healthcare companies hold the largest, more than 50.0% market share within the end-use category, in 2021, as a result of the rising indications and demands for cost-effective clinical trial and product analysis strategies

• North America dominated the market in 2021 and generated more than 59.0% share of the total revenue, as a result of its well-established advanced healthcare infrastructure and large expenditure in R&D activities. Furthermore, Europe would see the fastest rate of growth during the forecast period

• By engaging in partnerships, acquisitions, mergers, and product launches, key companies also help the market to expand. For instance, in 2021, Med able collaborated with the digital biomarkers business Aural Analytics to measure distant speech patterns and monitor their well-being and stage of decline



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Report Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Digital BiomarkersMarket Summary, 2021
Chapter 3 Digital Biomarkers Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Digital Biomarkers Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increased Popularity of Recent Innovations and Remote Technologies
3.3.1.2 Rising Usage of Smartphones and The Emergence of New Wearables
3.3.1.3 Expanding Therapeutic Area Application
3.3.1.4 Increasing Investment in Decentralized Clinical Trials
3.3.2 Market Restraints Analysis
3.3.2.1 Concerns about Data Privacy
3.3.2.1 Lack of Awareness and Poor Skilled Professionals in Emerging Economics
3.4 Digital Biomarkers Market Analysis Tools: Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Threat Of Substitutes
3.4.4 Threat Of New Entrants
3.4.5 Competitive Rivalry
3.5 Pestel Analysis
3.5.1 Political & Legal Landscape
3.5.2 Social Landscape
3.5.3 Technology Landscape
3.5.4 Environmental Analysis
3.6 Regulatory Framework
3.7 Technology Overview
3.8 Pricing Analysis
3.9 Covid-19 Impact Analysis
3.9.1 Current And Future Impact Analysis
3.9.2 Impact Of Covid-19 On Market Players
Chapter 4 Competitive Landscape
4.1 Market participation categorization
4.2 Public Companies
4.2.1 Company Market Position Analysis
4.2.2 Synergy Analysis: Major Deals & Strategic Alliances
4.3 Detailed list of market players
Chapter 5 Digital Biomarkers Market: Segment Analysis, by type, 2017 - 2030 (USD Million)
5.1 Type Movement Analysis, 2021 & 2030
5.1.1 Wearable
5.1.1.1 Wearable Market Estimates and Forecasts, 2017 - 2030 (Million)
5.1.2 Mobile Based Applications
5.1.2.1 Mobile Based Applications Market Estimates and Forecasts, 2017 - 2030 (Million)
5.1.3 Sensors
5.1.3.1 Sensors Market Estimates and Forecasts, 2017 - 2030 (Million)
5.1.4 Others
5.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 6 Digital Biomarkers Market: Segment Analysis, by Clinical Practice, 2017 - 2030 (USD Million)
6.1 Clinical Practice Movement Analysis, 2021 & 2030
6.1.1 Diagnostic Digital Biomarkers
6.1.1.1 Diagnostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
6.1.2 Monitoring Digital Biomarkers
6.1.2.1 Monitoring Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
6.1.3 Predictive and Prognostic Digital Biomarkers
6.1.3.1 Predictive and Prognostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
6.1.4 Others
6.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 7 Digital Biomarkers Market: Segment Analysis, by Therapeutic Area, 2017 - 2030 (USD Million)
7.1 Therapeutic Area Movement Analysis, 2021 & 2030
7.1.1 Cardiovascular and Metabolic Disorders (CVMD)
7.1.1.1 Cardiovascular and Metabolic Disorders (CVMD) Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.2 Respiratory Disorders
7.1.2.1 Respiratory Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.3 Psychiatric Disorders
7.1.3.1 Psychiatric Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.4 Sleep & Movement Disease
7.1.4.1 Sleep & Movement Disease Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.5 Neurological Disorders
7.1.5.1 Neurological Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.6 Musculoskeletal Disorders
7.1.6.1 Musculoskeletal Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.7 Others
7.1.7.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 8 Digital Biomarkers Market: Segment Analysis, by End-Use, 2017 - 2030 (USD Million)
8.1 End-Use Movement Analysis, 2021 & 2030
8.1.1 Healthcare Companies
8.1.1.1 Healthcare Companies Market Estimates and Forecasts, 2017 - 2030 (Million)
8.1.2 Healthcare Providers
8.1.2.1 Healthcare ProvidersMarket Estimates and Forecasts, 2017 - 2030 (Million)
8.1.3 Payers
8.1.3.1 Payers Market Estimates and Forecasts, 2017 - 2030 (Million)
8.1.4 Others
8.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 9 Digital Biomarkers Market: Regional Market Analysis, by type, clinical practice, therapeutic area, and end-Use, 2017 - 2030 (USD Million)
9.1 Market Size, & Forecasts, Volume, and Trend Analysis, 2017 to 2030
9.2 North America
9.2.1 North America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.2.2 U.S.
9.2.2.1 U.S. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.2.3 Canada
9.2.3.1 Canada Digital Biomarkers Market Estimates and Forecasts, 2017 -2030 (Million)
9.3 Europe
9.3.1 Europe Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.2 U.K.
9.3.2.1 U.K. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.3 Germany
9.3.3.1 Germany Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.4 Netherlands
9.3.4.1 Netherlands Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.5 Italy
9.3.5.1 Italy Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.6 Switzerland
9.3.6.1 Switzerland Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.2 Japan
9.4.2.1 Japan Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.3 China
9.4.3.1 China Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.4 Australia
9.4.4.1 Australia Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.5 India
9.4.5.1 India Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.6 South Korea
9.4.6.1 South Korea Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.5 Latin America
9.5.1 Latin America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.5.2 Brazil
9.5.2.1 Brazil Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.5.3 Mexico
9.5.3.1 Mexico Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.6 MEA
9.6.1 MEA Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.6.2 South Africa
9.6.2.1 South Africa Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.6.3 Israel
9.6.3.1 Israel Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 10 Company Profiles
10.1 ActiGraph LLC
10.1.1 Company Overview
10.1.2 Financial Performance
10.1.3 Product Benchmarking
10.1.4 Strategic Initiatives
10.2 AliveCor Inc
10.2.1 Company Overview
10.2.2 Financial Performance
10.2.3 Product Benchmarking
10.2.4 Strategic Initiatives
10.3 Koneksa
10.3.1 Company Overview
10.3.2 Financial Performance
10.3.3 Product Benchmarking
10.3.4 Strategic Initiatives
10.4 Amgen Inc.
10.4.1 Company Overview
10.4.2 Financial Performance
10.4.3 Product Benchmarking
10.4.4 Strategic Initiatives
10.5 Biogen Inc.
10.5.1 Company Overview
10.5.2 Financial Performance
10.5.3 Product Benchmarking
10.5.4 Strategic Initiatives
10.6 Altoida Inc
10.6.1 Company Overview
10.6.2 Financial Performance
10.6.3 Product Benchmarking
10.6.4 Strategic Initiatives
10.7 IXICO plc
10.7.1 Company Overview
10.7.2 Financial Performance
10.7.3 Product Benchmarking
10.7.4 Strategic Initiatives
10.8 Adherium Limited
10.8.1 Company Overview
10.8.2 Financial Performance
10.8.3 Product Benchmarking
10.8.4 Strategic Initiatives
10.9 Empatica Inc
10.9.1 Company Overview
10.9.2 Financial Performance
10.9.3 Product Benchmarking
10.9.4 Strategic Initiatives
10.10 Huma
10.10.1 Company Overview
10.10.2 Financial Performance
10.10.3 Product Benchmarking
10.10.4 Strategic Initiatives
10.11 VivoSense
10.11.1 Company Overview
10.11.2 Financial Performance
10.11.3 Product Benchmarking
10.11.4 Strategic Initiatives
10.12 ResApp (Pfizer)
10.12.1 Company Overview
10.12.2 Financial Performance
10.12.3 Product Benchmarking
10.12.4 Strategic Initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

Grand View Research社のバイオ薬物分野での最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る